Edition:
United States

Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

3.69USD
25 Apr 2017
Change (% chg)

$0.09 (+2.64%)
Prev Close
$3.60
Open
$3.67
Day's High
$3.72
Day's Low
$3.62
Volume
9,550
Avg. Vol
14,988
52-wk High
$7.49
52-wk Low
$2.99

Select another date:

Thu, Apr 20 2017

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

* Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax

BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities

* Agenus restructures business to sharpen focus on clinical development of cancer therapies

BRIEF-Incyte and Agenus amend collaboration agreement

* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs

BRIEF-Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus

* Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing Source text - http://bit.ly/2lpg9SS Further company coverage:

BRIEF-QVT Financial reports 5.08 pct passive stake in Agenus

* QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing Source text - http://bit.ly/2jHW6OQ Further company coverage:

BRIEF-Agenus files for offering of up to 157,513 shares by selling stockholder

* Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing Source text: (http://bit.ly/2jIMpis) Further company coverage:

BRIEF-Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

* Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

BRIEF-Agenus reports Q3 loss per share $0.47

* Agenus reports third quarter financial results and recent highlights

Select another date:

More From Around the Web